Blanka Bugajewska
Research Subjects
Research Interests
Blanka Bugajewska has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Anna Moniuszko-Malinowska
Klinika Chorób Zakaźnych i Neuroinfekcji, Uniwersytet Medyczny w Białymstoku
1 shared publication- Bogumiła Czartoryska-Arłukowicz
Maria Sklodowska-Curie Bialystok Oncology Centre,15-027 Bialystok, Poland
1 shared publication - Kaja Bors
Klinika Chorób Zakaźnych i Neuroinfekcji, Uniwersytet Medyczny w Białymstoku
1 shared publication Karol Borawski
Klinika Chorób Zakaźnych i Neuroinfekcji, Uniwersytet Medyczny w Białymstoku
1 shared publication- Katarzyna Pogoda
Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
1 shared publication - Michał Nienałtowski
Klinika Chorób Zakaźnych i Neuroinfekcji, Uniwersytet Medyczny w Białymstoku
1 shared publication
Latest Publications
- Open Access
- 6 November 2026
- Published by MDPI AG in Antibodies
- Vol. 15 (6) , 105
Denosumab in Breast Cancer: Immunobiology, Clinical Evidence and Future Perspectives
Bone is the most common site of distant relapse in breast cancer, and skeletal-related events (SREs) remain a major source of morbidity and reduced quality of life in patients with bone-metastatic disease. Denosumab, a fully human IgG2 monoclonal antibody against receptor activator of nuclear factor-κB ligand (RANKL), interrupts osteoclast-driven bone resorption upstream of the bisphosphonate mechanism of action and has demonstrated superiority over zoledronic acid in preventing SREs in pivotal phase III trials. Beyond this well-established antiresorptive role, RANK/RANKL signaling has been implicated in mammary tumorigenesis and modulation of the tumor immune microenvironment, and recent window-of-opportunity studies have shown that short-term denosumab increases tumor-infiltrating lymphocytes in human breast tumors—a translational finding that has not yet been linked to a demonstrated clinical benefit. This narrative review synthesizes the pharmacology of denosumab; the biological rationale linking RANKL to immune-cell function in the breast; the pivotal and contemporary clinical evidence in metastatic and early breast cancer, including the divergent D-CARE and ABCSG-18 adjuvant trials and the 2026 REDUSE dosing-interval data; and practical considerations distinguishing denosumab’s evidentiary position in metastatic disease, cancer treatment-induced bone loss, and adjuvant disease modification. We also discuss why preclinical immune synergy has not been reproduced clinically and outline priorities for biomarker-selected trials, immunotherapy combinations, dose de-escalation, and MRONJ risk stratification. Throughout, we distinguish established clinical applications from translational and hypothesis-generating findings, and highlight methodological limitations—including small subgroup sizes, retrospective design, and unpublished congress data—that should temper interpretation of several recent findings before they inform clinical practice or future trial design.
- 6 November 2026
- Published by MDPI AG in Antibodies
- Vol. 15 (6) , 105
Open AccessDenosumab in Breast Cancer: Immunobiology, Clinical Evidence and Future Perspectives
Bone is the most common site of distant relapse in breast cancer, and skeletal-related events (SREs) remain a major source of morbidity and reduced quality of life in patients with bone-metastatic disease. Denosumab, a fully human IgG2 monoclonal antibody against receptor activator of nuclear factor-κB ligand (RANKL), interrupts osteoclast-driven bone resorption upstream of the bisphosphonate mechanism of action and has demonstrated superiority over zoledronic acid in preventing SREs in pivotal phase III trials. Beyond this well-established antiresorptive role, RANK/RANKL signaling has been implicated in mammary tumorigenesis and modulation of the tumor immune microenvironment, and recent window-of-opportunity studies have shown that short-term denosumab increases tumor-infiltrating lymphocytes in human breast tumors—a translational finding that has not yet been linked to a demonstrated clinical benefit. This narrative review synthesizes the pharmacology of denosumab; the biological rationale linking RANKL to immune-cell function in the breast; the pivotal and contemporary clinical evidence in metastatic and early breast cancer, including the divergent D-CARE and ABCSG-18 adjuvant trials and the 2026 REDUSE dosing-interval data; and practical considerations distinguishing denosumab’s evidentiary position in metastatic disease, cancer treatment-induced bone loss, and adjuvant disease modification. We also discuss why preclinical immune synergy has not been reproduced clinically and outline priorities for biomarker-selected trials, immunotherapy combinations, dose de-escalation, and MRONJ risk stratification. Throughout, we distinguish established clinical applications from translational and hypothesis-generating findings, and highlight methodological limitations—including small subgroup sizes, retrospective design, and unpublished congress data—that should temper interpretation of several recent findings before they inform clinical practice or future trial design.
- Open Access
- 13 February 2025
- Published by National Institute of Public Health NIH (National Research Institute) in Przeglad Epidemiologiczny
- Vol. 79 (1) , 13-27
Bioterrorism: current situation
Bioterrorism is the phenomenon of the unlawful and intentional use of biological agents, such as pathogenic microorganisms or toxins, to cause health, economic and social harm. This paper discusses the basics of the CDC's classification of potential agents used in bioterrorism with a focus on the description of the most dangerous Category A pathogens. This includes their general characteristics, potential for use as biological weapons, and the most current forms of diagnosis, treatment and prevention of diseases caused by them. The paper highlights the role of international organisations, such as the UN and Interpol, in monitoring and countering bioterrorism threats. The paper also includes information about bioterrorist attacks in recent years and possible potential threats in the future. A narrative review of scientific literature, government reports and data from international agencies was conducted. The results highlight the need for continuous monitoring of bioterrorist threats, the development of effective response schemes and investment in protective measures. Despite its rarity, bioterrorism has a high potential effectiveness in causing social panic and economic destabilisation, making it one of the most serious challenges facing the world today.
- 13 February 2025
- Published by National Institute of Public Health NIH (National Research Institute) in Przeglad Epidemiologiczny
- Vol. 79 (1) , 13-27
Open AccessBioterrorism: current situation
Bioterrorism is the phenomenon of the unlawful and intentional use of biological agents, such as pathogenic microorganisms or toxins, to cause health, economic and social harm. This paper discusses the basics of the CDC's classification of potential agents used in bioterrorism with a focus on the description of the most dangerous Category A pathogens. This includes their general characteristics, potential for use as biological weapons, and the most current forms of diagnosis, treatment and prevention of diseases caused by them. The paper highlights the role of international organisations, such as the UN and Interpol, in monitoring and countering bioterrorism threats. The paper also includes information about bioterrorist attacks in recent years and possible potential threats in the future. A narrative review of scientific literature, government reports and data from international agencies was conducted. The results highlight the need for continuous monitoring of bioterrorist threats, the development of effective response schemes and investment in protective measures. Despite its rarity, bioterrorism has a high potential effectiveness in causing social panic and economic destabilisation, making it one of the most serious challenges facing the world today.